Kinetic analysis on the sensitivity of glucose- or glyoxal-induced LDL glycation to the inhibitory effect of Psidium guajava extract in a physiomimic system

Chiu-Lan Hsieh, Ming Hua Yang, Charng Cherng Chyau, Chun Hon Chiu, Hui Er Wang, Yuh Charn Lin, Wen Ta Chiu, Robert Y. Peng

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Experimentation with a physiomimic system and kinetic analysis exhibited four distinct reaction phases in LDL glycation despite of the type of inducer: glucose or glyoxal. LDL glycation was more sensitive to a status of hyperglycemia (such as 400 mg glucose/100 mL) as evidenced by the reaction order of 0.53. Glucose reacted intensively in the Initial Phase (reaction period 0-2 h) which was identified to result from a parallel mechanism involving both the direct Schiff's product formation and the auto-oxidative cleavages. In contrast, a physiological level of glyoxal revealed merely a reaction order of only 0.09, implicitly indicating a far less sensitive glycation which can be attributed to a mechanism proceeding simply through a molecular Schiff's reaction. On treatment with Psidium guajava L. aqueous extract (PE) (0.01-0.625 mg/mL), a rather unique and significant inhibitory characteristic on LDL glycation was observed with a dose-dependent manner. We attributed such an effect of PE to its distinct abundance of polyphenolic content (165.61 ± 10.39 mg gallic acid equivalent (GAE)/g). Conclusively, PE is an excellent anti-LDL glycative agent whose potential therapeutic uses can be extended to the prevention of a variety of cardiovascular and neurodegenerative diseases associated with glycations.

Original languageEnglish
Pages (from-to)92-100
Number of pages9
JournalBioSystems
Volume88
Issue number1-2
DOIs
Publication statusPublished - 2007 Mar 1

Fingerprint

Glyoxal
Psidium
Glucose
Kinetics
Neurodegenerative diseases
Gallic Acid
Therapeutic Uses
Hyperglycemia
Neurodegenerative Diseases
Distinct
Cardiovascular Diseases
Parallel Mechanism
Direct Product
Acids
Experimentation
Dose
oxidized low density lipoprotein
Dependent

All Science Journal Classification (ASJC) codes

  • Statistics and Probability
  • Modelling and Simulation
  • Biochemistry, Genetics and Molecular Biology(all)
  • Applied Mathematics

Cite this

Hsieh, Chiu-Lan ; Yang, Ming Hua ; Chyau, Charng Cherng ; Chiu, Chun Hon ; Wang, Hui Er ; Lin, Yuh Charn ; Chiu, Wen Ta ; Peng, Robert Y. / Kinetic analysis on the sensitivity of glucose- or glyoxal-induced LDL glycation to the inhibitory effect of Psidium guajava extract in a physiomimic system. In: BioSystems. 2007 ; Vol. 88, No. 1-2. pp. 92-100.
@article{4dbad66968204ca1856691c1fb54b8b3,
title = "Kinetic analysis on the sensitivity of glucose- or glyoxal-induced LDL glycation to the inhibitory effect of Psidium guajava extract in a physiomimic system",
abstract = "Experimentation with a physiomimic system and kinetic analysis exhibited four distinct reaction phases in LDL glycation despite of the type of inducer: glucose or glyoxal. LDL glycation was more sensitive to a status of hyperglycemia (such as 400 mg glucose/100 mL) as evidenced by the reaction order of 0.53. Glucose reacted intensively in the Initial Phase (reaction period 0-2 h) which was identified to result from a parallel mechanism involving both the direct Schiff's product formation and the auto-oxidative cleavages. In contrast, a physiological level of glyoxal revealed merely a reaction order of only 0.09, implicitly indicating a far less sensitive glycation which can be attributed to a mechanism proceeding simply through a molecular Schiff's reaction. On treatment with Psidium guajava L. aqueous extract (PE) (0.01-0.625 mg/mL), a rather unique and significant inhibitory characteristic on LDL glycation was observed with a dose-dependent manner. We attributed such an effect of PE to its distinct abundance of polyphenolic content (165.61 ± 10.39 mg gallic acid equivalent (GAE)/g). Conclusively, PE is an excellent anti-LDL glycative agent whose potential therapeutic uses can be extended to the prevention of a variety of cardiovascular and neurodegenerative diseases associated with glycations.",
author = "Chiu-Lan Hsieh and Yang, {Ming Hua} and Chyau, {Charng Cherng} and Chiu, {Chun Hon} and Wang, {Hui Er} and Lin, {Yuh Charn} and Chiu, {Wen Ta} and Peng, {Robert Y.}",
year = "2007",
month = "3",
day = "1",
doi = "10.1016/j.biosystems.2006.04.004",
language = "English",
volume = "88",
pages = "92--100",
journal = "BioSystems",
issn = "0303-2647",
publisher = "Elsevier Ireland Ltd",
number = "1-2",

}

Kinetic analysis on the sensitivity of glucose- or glyoxal-induced LDL glycation to the inhibitory effect of Psidium guajava extract in a physiomimic system. / Hsieh, Chiu-Lan; Yang, Ming Hua; Chyau, Charng Cherng; Chiu, Chun Hon; Wang, Hui Er; Lin, Yuh Charn; Chiu, Wen Ta; Peng, Robert Y.

In: BioSystems, Vol. 88, No. 1-2, 01.03.2007, p. 92-100.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Kinetic analysis on the sensitivity of glucose- or glyoxal-induced LDL glycation to the inhibitory effect of Psidium guajava extract in a physiomimic system

AU - Hsieh, Chiu-Lan

AU - Yang, Ming Hua

AU - Chyau, Charng Cherng

AU - Chiu, Chun Hon

AU - Wang, Hui Er

AU - Lin, Yuh Charn

AU - Chiu, Wen Ta

AU - Peng, Robert Y.

PY - 2007/3/1

Y1 - 2007/3/1

N2 - Experimentation with a physiomimic system and kinetic analysis exhibited four distinct reaction phases in LDL glycation despite of the type of inducer: glucose or glyoxal. LDL glycation was more sensitive to a status of hyperglycemia (such as 400 mg glucose/100 mL) as evidenced by the reaction order of 0.53. Glucose reacted intensively in the Initial Phase (reaction period 0-2 h) which was identified to result from a parallel mechanism involving both the direct Schiff's product formation and the auto-oxidative cleavages. In contrast, a physiological level of glyoxal revealed merely a reaction order of only 0.09, implicitly indicating a far less sensitive glycation which can be attributed to a mechanism proceeding simply through a molecular Schiff's reaction. On treatment with Psidium guajava L. aqueous extract (PE) (0.01-0.625 mg/mL), a rather unique and significant inhibitory characteristic on LDL glycation was observed with a dose-dependent manner. We attributed such an effect of PE to its distinct abundance of polyphenolic content (165.61 ± 10.39 mg gallic acid equivalent (GAE)/g). Conclusively, PE is an excellent anti-LDL glycative agent whose potential therapeutic uses can be extended to the prevention of a variety of cardiovascular and neurodegenerative diseases associated with glycations.

AB - Experimentation with a physiomimic system and kinetic analysis exhibited four distinct reaction phases in LDL glycation despite of the type of inducer: glucose or glyoxal. LDL glycation was more sensitive to a status of hyperglycemia (such as 400 mg glucose/100 mL) as evidenced by the reaction order of 0.53. Glucose reacted intensively in the Initial Phase (reaction period 0-2 h) which was identified to result from a parallel mechanism involving both the direct Schiff's product formation and the auto-oxidative cleavages. In contrast, a physiological level of glyoxal revealed merely a reaction order of only 0.09, implicitly indicating a far less sensitive glycation which can be attributed to a mechanism proceeding simply through a molecular Schiff's reaction. On treatment with Psidium guajava L. aqueous extract (PE) (0.01-0.625 mg/mL), a rather unique and significant inhibitory characteristic on LDL glycation was observed with a dose-dependent manner. We attributed such an effect of PE to its distinct abundance of polyphenolic content (165.61 ± 10.39 mg gallic acid equivalent (GAE)/g). Conclusively, PE is an excellent anti-LDL glycative agent whose potential therapeutic uses can be extended to the prevention of a variety of cardiovascular and neurodegenerative diseases associated with glycations.

UR - http://www.scopus.com/inward/record.url?scp=33846885479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846885479&partnerID=8YFLogxK

U2 - 10.1016/j.biosystems.2006.04.004

DO - 10.1016/j.biosystems.2006.04.004

M3 - Article

C2 - 16806668

AN - SCOPUS:33846885479

VL - 88

SP - 92

EP - 100

JO - BioSystems

JF - BioSystems

SN - 0303-2647

IS - 1-2

ER -